180 Life Sciences Files 8-K
Ticker: FRMM · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1690080
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-reporting
TL;DR
180 Life Sciences filed a routine 8-K, no major news.
AI Summary
On March 13, 2024, 180 Life Sciences Corp. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by 180 Life Sciences Corp. to the SEC, without disclosing new material information.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- March 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Palo Alto, CA (location) — Business Address City and State
FAQ
What is the primary purpose of this 8-K filing for 180 Life Sciences Corp.?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of March 13, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is March 13, 2024.
In which state was 180 Life Sciences Corp. incorporated?
180 Life Sciences Corp. was incorporated in Delaware.
What is the business address of 180 Life Sciences Corp. mentioned in the filing?
The business address mentioned is 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306.
Does this 8-K filing disclose any specific new financial results or material business developments?
No, this 8-K filing does not appear to disclose specific new financial results or material business developments beyond standard reporting categories.
Filing Stats: 821 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2024-03-14 08:30:11
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
- $1.00 — iled to maintain a minimum bid price of $1.00 over the previous 30 consecutive busine
- $2,500,000 — intain stockholders' equity of at least $2,500,000. In the Company's Quarterly Report on F
- $149,327 — ny reported a stockholders' deficit of ($149,327), which is below the minimum stockholde
Filing Documents
- ea0201776-8k_180life.htm (8-K) — 32KB
- ea020177601ex99-1_180life.htm (EX-99.1) — 4KB
- 0001213900-24-022381.txt ( ) — 252KB
- atnf-20240313.xsd (EX-101.SCH) — 4KB
- atnf-20240313_def.xml (EX-101.DEF) — 26KB
- atnf-20240313_lab.xml (EX-101.LAB) — 36KB
- atnf-20240313_pre.xml (EX-101.PRE) — 25KB
- ea0201776-8k_180life_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. As previously disclosed, on September 7, 2023, 180 Life Sciences Corp. (the " Company ") received a notification letter from The Nasdaq Stock Market LLC (" Nasdaq ") indicating that the Company's common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). On March 13, 2024, the Company received a letter from Nasdaq notifying the Company that it has regained full compliance with the minimum bid price for continued listing on Nasdaq, pursuant to Nasdaq Listing Rule 5550(a)(2)(the " Minimum Bid Price Requirement "), because Nasdaq has determined that for 10 consecutive business days, the closing bid price of the Company's common stock was at or above $1.00 per share. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed. Notwithstanding the above, and as discussed in the Current Reports on Form 8-K filed with the Securities and Exchange Commission on November 16, 2023 and January 16, 2024, the Company remains out of compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the " Rule "), which requires companies listed on the Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000. In the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, the Company reported a stockholders' deficit of ($149,327), which is below the minimum stockholders' equity required for continued listing pursuant to the Rule. Additionally, the Company does not meet the alternative Nasdaq continued listing standards under Nasdaq Listing Rules. The Company is currently evaluating various courses of action to regain compliance and is hopeful that it can regain compliance with Nasdaq's minimum stockholders' equity standard within the compliance period approved by Nasdaq; however, t
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated March 14, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 14, 2024 180 LIFE SCIENCES CORP. By: /s/ James N. Woody, M.D., Ph.D. Name: James N. Woody, M.D., Ph.D. Title: Chief Executive Officer 3